Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
December 6, 2018
Kuros Reports Publication of MagnetOs Data Demonstrating Equivalence to Autologous Bone in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs ...
December 6, 2018
Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients
PARIS--(BUSINESS WIRE)-Abivax (ABVX.PA) (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop treatments for inflammatory/autoimmune diseases, infectious diseases and cancer, ...
December 6, 2018
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
TEL AVIV, Israel, December 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it ...
December 6, 2018
Athenex to Host an R&D Day on December 17 in New York
BUFFALO, N.Y., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
December 6, 2018
Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
HOPKINTON, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
December 6, 2018
Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in ...
December 6, 2018
RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical ...
December 6, 2018
VALNEVA and HOOKIPA Sign a Collaboration and Manufacturing Agreement
Saint-Herblain, France, and Vienna, Austria, December 06, 2018 - Valneva Sweden AB, the Swedish subsidiary of Valneva SE ("Valneva"), and HOOKIPA Pharma Inc. ("HOOKIPA") today ...
December 5, 2018
TATAA Biocenter Expands Its Next-Generation Sequencing Offerings with HTG Molecular Diagnostics' Unique HTG EdgeSeq System
GÖTEBORG, Sweden and TUSCON, Ariz., Dec. 05, 2018 (GLOBE NEWSWIRE) -- TATAA Biocenter, Europe's leading provider of genomic services, and HTG Molecular Diagnostics, Inc (HTG) ...
December 5, 2018
Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
BOSTON and LONDON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and ...
December 5, 2018
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing ...
December 5, 2018
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
LAVAL, QC , Dec. 5, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") today confirmed its decision to formally pursue Alström ...
December 5, 2018
Transgene Announces Upcoming Investor Meetings
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (TNG.PA) today announces that Management will participate in the upcoming investor events set out below. Transgene will meet institutional investors at ...
December 4, 2018
RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
December 4, 2018
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
December 4, 2018
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of ...
December 4, 2018
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
December 4, 2018
Eiger BioPharmaceuticals to Host R&D Day in New York City
PALO ALTO, Calif., Dec. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...
December 4, 2018
Novus Therapeutics Announces Formation of Scientific Advisory Board
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
December 4, 2018
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
Page 1 of 117